Read by QxMD icon Read

Red cell alloantibody

Prabitha Natarajan, Jingchun Liu, Manjula Santhanakrishnan, David R Gibb, Lewis M Slater, Jeanne E Hendrickson
BACKGROUND: Few therapeutic options currently exist to prevent or to mitigate transfusion-associated red blood cell (RBC) alloimmunization. We hypothesized that bortezomib, a proteasome inhibitor currently being utilized for HLA alloantibody and ADAMTS13 autoantibody reduction, may be beneficial in a transfusion setting. Herein, we utilized a reductionist murine model to test our hypothesis that bortezomib would decrease RBC alloimmune responses. STUDY DESIGN AND METHODS: Wild-type mice were treated with bortezomib or saline and transfused with murine RBCs expressing the human KEL glycoprotein...
October 13, 2016: Transfusion
S Morris, M H Yudin, J Callum, A Alam, J Herold, Y Lin
OBJECTIVES: To evaluate the current state of transfusion medicine (TM) knowledge among obstetricians using a valid assessment tool. BACKGROUND: Transfusion issues are common in obstetrical patients. METHODS: Knowledge topics were identified and rated by experts in obstetrics, anaesthesia, haematology and TM using a modified Delphi method. A knowledge assessment tool was developed and validated during pilot testing. The assessment tool, consisting of 15 multiple choice questions, was administered electronically to members of the Society of Obstetricians and Gynaecologists of Canada (SOGC)...
September 26, 2016: Transfusion Medicine
Sumaiya Adam, Hennie Lombaard
BACKGROUND: Minor red blood cell antibodies are becoming a more common cause of hemolytic disease of the newborn. Anti-U are a rare alloantibody found almost exclusively in people of black descent. There is limited experience to guide the management of pregnancies complicated by anti-U. Furthermore, there is often no suitable cross-matched blood available for transfusion of a patient with anti-U. CASE REPORT: A 21-year-old P0G1 presented at 25 weeks' gestation with D- disease in pregnancy...
September 23, 2016: Transfusion
Abhinav Arneja, Juan E Salazar, Wenyu Jiang, Jeanne E Hendrickson, James C Zimring, Chance John Luckey
No abstract text is available yet for this article.
August 4, 2016: Haematologica
Dorothea Evers, Jaap Jan Zwaginga, Janneke Tijmensen, Rutger A Middelburg, Masja de Haas, Karen M K de Vooght, Daan van de Kerkhof, Otto Visser, Nathalie C V Péquériaux, Francisca Hudig, Johanna G van der Bom
Red cell alloimmunization may induce severe hemolytic side effects. Identification of risk modifying conditions will help tailor preventative strategies. This study aims to quantify the associations of hematological malignancies and solid cancers with red cell alloimmunization in patients receiving red cell transfusions. We performed a nested multicenter case-control study in a source population of 24,063 patients receiving their first and subsequent red cell transfusions during an eight year follow-up period...
September 15, 2016: Haematologica
Heather L Howie, Meghan Delaney, Xiaohong Wang, Lay See Er, Gestur Vidarsson, Tamara C Stegmann, Linda Kapp, Jenna N Lebedev, Yanyun Wu, James P AuBuchon, James C Zimring
BACKGROUND: Human immunoglobulin G (IgG) includes four different subtypes (IgG1, IgG2, IgG3, and IgG4), and it is also now appreciated that there are genetic variations within IgG subtypes (called isoallotypes). Twenty-nine different isoallotypes have been described, with 7, 4, 15, and 3 isoallotypes described for IgG1, IgG2, IgG3, and IgG4, respectively. The reactivity of anti-IgG with different isoallotypes has not been characterized. STUDY DESIGN AND METHODS: A novel monoclonal anti-K antibody (PugetSound Monoclonal Antibody 1 [PUMA1]) was isolated and sequenced, and a panel of PUMA1 variants was expressed, consisting of the 29 known IgG isoallotypes...
September 16, 2016: Transfusion
Ashish Jain, Ajju Agnihotri, Neelam Marwaha, Ratti Ram Sharma
INTRODUCTION: Red cell allo- and auto-immunization is a well recognized problem in multi-transfused thalassemic patients. We conducted this study on 301 multi-transfused thalassemic patients under the Thalassemia Transfusion Programme of Advanced Pediatric Centre of PGIMER. AIMS AND OBJECTIVES: The study was designed to determine the frequency of alloimmunization and autoimmunization in multi-transfused thalassemic patients and to establish the specificity of alloantibody to red cell antigens, if alloimmunization is detected...
July 2016: Asian Journal of Transfusion Science
Raj Nath Makroo, Soma Agrawal, Aakanksha Bhatia, Mohit Chowdhry, Uday Kumar Thakur
BACKGROUND: Red cell alloimmunization is an acknowledged complication of blood transfusion. Current transfusion practices for thalassemia do not cater to this risk. Serological phenotyping is usually not reliable in these cases unless performed before the first transfusion. Under such circumstances, molecular blood grouping is an effective alternative. AIM: To perform molecular blood group genotyping in chronically transfused thalassemia patients and assess the risk of antigenic exposure and incidence of alloimmunization with current transfusion protocols...
July 2016: Asian Journal of Transfusion Science
Meenu Bajpai, Shruti Gupta, Priyanka Jain
INTRODUCTION: Transfusion support is vital to the management of patients with liver diseases. Repeated transfusions are associated with many risks such as transfusion-transmitted infection, transfusion immunomodulation, and alloimmunization. MATERIALS AND METHODS: A retrospective data analysis of antibody screening and identification was done from February 2012 to February 2014 to determine the frequency and specificity of irregular red-cell antibodies in multitransfused liver disease patients...
July 2016: Asian Journal of Transfusion Science
Cecilia González, Rosa Esteban, Carme Canals, Eduardo Muñiz-Díaz, Núria Nogués
BACKGROUND: The identification of erythrocyte antibodies in the serum of patients rely on panels of human red blood cells (RBCs), which coexpress many antigens and are not easily available for low-incidence blood group phenotypes. These problems have been addressed by generating cell lines expressing unique blood group antigens, which may be used as an alternative to human RBCs. However, the use of cell lines implies several drawbacks, like the requirement of cell culture facilities and the high cost of cryopreservation...
2016: PloS One
Lance A Williams, Robin G Lorenz, Absar Tahir, Huy P Pham, Marisa B Marques
OBJECTIVES: Alloantibody formation secondary to transfusion in patients with sickle cell disease (SCD) is a well-known phenomenon. Pretransfusion testing (eg, "antibody screening") protects patients from receiving incompatible red blood cell transfusions. Because alloantibodies have a tendency to evanesce (ie, become undetectable over time), however, this phenomenon puts patients at risk of a delayed hemolytic transfusion reaction or even acute hemolysis. METHODS: We evaluated the records of 71 patients with SCD with alloantibodies detected during a 2-year period to describe their most common specificities and their rate of evanescence...
September 2016: Southern Medical Journal
Tik Nga Tong, Emeralda Burke-Murphy, Darinka Sakac, Jacob Pendergrast, Christine Cserti-Gazdewich, Vincent Laroche, Donald R Branch
BACKGROUND: Various versions of the monocyte monolayer assay (MMA) have been used to assess clinical significance of red blood cell (RBC) alloantibodies in transfusion for more than 35 years. However, the optimal conditions, including anticoagulant used for whole blood samples, temperature and duration of storage, and optimal pH for assessing the response of monocytes to antibody-bound RBCs, have never been clearly delineated. STUDY DESIGN AND METHODS: Whole blood from healthy donors was collected in ACD, EDTA, or heparin and stored at room temperature (RT) versus 4°C for up to 2 days...
August 21, 2016: Transfusion
Dorothea Evers, Johanna G van der Bom, Janneke Tijmensen, Rutger A Middelburg, Masja de Haas, Saurabh Zalpuri, Karen M K de Vooght, Daan van de Kerkhof, Otto Visser, Nathalie C V Péquériaux, Francisca Hudig, Jaap Jan Zwaginga
Red cell alloantigen exposure can cause alloantibody-associated morbidity. Murine models have suggested that inflammation modulates red cell alloimmunisation. This study quantifies alloimmunisation risks during infectious episodes in humans. We performed a multicentre case-control study within a source population of patients receiving their first and subsequent red cell transfusions during an 8-year follow-up period. Patients developing a first transfusion-induced red cell alloantibody (N = 505) were each compared with two similarly exposed, but non-alloimmunised controls (N = 1010) during a 5-week 'alloimmunisation risk period' using multivariate logistic regression analysis...
August 18, 2016: British Journal of Haematology
Thordis Kristinsdottir, Sveinn Kjartansson, Hildur Hardardottir, Thorbjorn Jonsson, Anna Margret Halldorsdottir
INTRODUCTION: Hemolytic disease of the fetus and newborn (HDFN) is caused by the destruction of fetal red blood cells due to red cell antibodies produced by the mother. HDFN can cause fetal hydrops during pregnancy or neonatal jaundice after birth. Direct Antiglobulin Test (DAT) detects antibodies bound to red cells and is a valuable test aiding in the diagnosis of HDFN. In Iceland DAT is routinely performed on cord blood or newborn blood samples if the mother is Rhesus D negative or has non-A/B red cell alloantibodies...
July 2016: Læknablađiđ
Jeanne E Hendrickson, Stephanie C Eisenbarth, Christopher A Tormey
PURPOSE OF REVIEW: To summarize recent discoveries from clinical studies and animal models that contribute to understanding the alloimmune response to non-ABO blood group antigens. RECENT FINDINGS: Several studies have confirmed high rates of alloimmunization among patients requiring chronic red blood cell (RBC) transfusion. Moreover, 'triggers' for alloantibody development in the transfusion setting have been identified, with a number of investigations linking recipient inflammation to a higher likelihood of alloimmunization...
November 2016: Current Opinion in Hematology
Meena Sidhu, Renu Bala, Naveen Akhtar, Vijay Sawhney
Screening and detection of clinically significant antibodies among antenatal women plays an important role in transfusion safety and preventing hemolytic disease of fetus and newborn. Routine screening of antenatal women for antibodies is not done in all blood centres of our country and so immunization rates are not known in pregnant women. We studied the prevalence of alloantibodies and titration of Anti D among antenatal multiparous women in Jammu region. In present prospective study, 750 antenatal multiparous women attending antenatal clinics were typed for ABO and D antigens...
September 2016: Indian Journal of Hematology & Blood Transfusion
Sebastián Ortiz, Maria T Orero, Karla Javier, Carolina Villegas, Irene Luna, Pedro Pérez, Mónica Roig, María López, Sofía Costa, Félix Carbonell, Rosa Collado, David Ivars, Mariano Linares
BACKGROUND: The incidence of alloimmunisation in myelodysplastic syndromes (MDS) during the era of supportive treatment ranges from 9 to 56%. However, it is unknown if the widespread use of hypomethylating agents has changed the risk of immunisation. The aim of this study is to evaluate the impact of azacitidine (AZA) therapy on red blood cell (RBC) alloimmunisation in transfused patients with MDS, myelodysplastic syndromes/myeloproliferative syndromes (MDS/MPS) and secondary acute myeloid leukaemia (AML)...
June 24, 2016: Blood Transfusion, Trasfusione del Sangue
Pierre Moncharmont, Grégory Barday, Jean-Yves Py, Francis Meyer
BACKGROUND: As transfusion in the elderly patients has increased over the last decades, and with the aim of improving blood policy, post-transfusion red blood cell alloimmunisation, a delayed serological transfusion reaction, was investigated in patients 80 years old or over. MATERIAL AND METHODS: For every adverse reaction to a transfusion, a report is sent to the French haemovigilance database. All cases of red blood cell alloimmunisation reported in the haemovigilance database were collected, and an analysis was performed on those cases in transfused patients 80 years old or over...
July 5, 2016: Blood Transfusion, Trasfusione del Sangue
Deepti Sachan, Aswin Kumar, Dinesh Jothimani, Mohamed Rela
Delayed serological transfusion reaction (DSTR) is defined as absence of clinical signs of hemolysis and demonstration of new, clinically-significant antibodies against red blood cells after a transfusion, by either positive direct antiglobulin test or positive antibody screen with newly identified RBC alloantibody. Various delayed hemolytic transfusion reaction cases are reported after red cell transfusions. However, the incidence of DSTR after platelet transfusion due to non-Rh(D) antibodies is not much documented...
June 2016: Indian Journal of Hematology & Blood Transfusion
Asral Wirda Ahmad Asnawi, Jameela Sathar, Rashidah Mohamed, Rohayu Deraman, Sri Kumaran, Shahada Sobah Abd Hamid, Muhd Zanapiah Zakaria
Clinical manifestations of sickle cell disease (SCD) arise from the tendency of the sickle haemoglobin to polymerize and deform red blood cells into the characteristic sickle shape. Sickle cell crisis is a devastating complication that may occur in patients with SCD. If not managed properly permanent organ damage and even death may be the final outcome. A case of a 32-year-old Nigerian lady, Gravida 1 Para 0 in her first trimester, with SCD who developed signs and symptoms of delayed haemolytic transfusion reaction after receiving packed red cell transfusion is demonstrated...
June 2016: Indian Journal of Hematology & Blood Transfusion
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"